• Solid growth of +10.1% in Theranostics and +9.2% in IVD
• Good export performance (outside the United States) materialized by an increase of +23.3%
• Cash level as of December 31, 2022: €6.4 million
Croissy-Beaubourg, January 16, 2023, 07:30 CET – THERADIAG (ISIN: FR0004197747, Mnemonic: ALTER), a company specializing in in vitro diagnostics of autoimmune diseases and Theranostics, today announces its annual turnover and its level of cash as of December 31, 2022.
If you wish to receive all of the company’s financial communications in real time, you can register directly by email at the following address: [email protected]